Chemotherapy for advanced pancreatic cancer
- VernacularTitle:晚期胰腺癌的化疗
- Author:
Rongbo LIN
;
Qiang CHEN
;
Nanfeng FAN
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Drug therapy
- From:
Journal of International Oncology
2008;35(4):291-293
- CountryChina
- Language:Chinese
-
Abstract:
Single-agent gemcitabine, the standard chemotherapy for pancreatic cancer, has only mod-est effect. Gemcitabine has been combined with a variety of cytotoxic agents and targeted agents. Most phase Ⅲ studies, however, have failed to show improved survival compared with gemcitabine alone. One phase Ⅲ study has shown improved survival in advanced pancreatic cancer by adding erlotinib to gemcitabine. Studies evalua-ting non-gemcitabine-based regimens have showed considerable promise.
